RLAY Stock Forecast 2025-2026
Distance to RLAY Price Targets
RLAY Price Momentum
🤔 Considering Relay Therapeutics (RLAY)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest RLAY Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, RLAY has a bullish consensus with a median price target of $18.00 (ranging from $12.00 to $30.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $3.66, the median forecast implies a 391.8% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Bradley Canino at Stifel, projecting a 719.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RLAY Analyst Ratings
RLAY Price Target Range
Latest RLAY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RLAY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $16.00 |
| Feb 27, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $18.00 |
| Feb 27, 2025 | Stifel | Bradley Canino | Buy | Maintains | $23.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $16.00 |
| Dec 12, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $21.00 |
| Dec 5, 2024 | Leerink Partners | Outperform | Maintains | $0.00 | |
| Dec 4, 2024 | Leerink Partners | Christopher Liu | Outperform | Maintains | $18.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $16.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $20.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $19.00 |
| Sep 17, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $21.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $19.00 |
| Sep 16, 2024 | Stifel | Bradley Canino | Buy | Reiterates | $28.00 |
| Sep 10, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $24.00 |
| Sep 10, 2024 | Oppenheimer | Matthew Biegler | Perform | Downgrade | $0.00 |
| Sep 10, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $17.00 |
| Sep 10, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $21.00 |
| Sep 10, 2024 | Goldman Sachs | Salveen Richter | Buy | Reinstates | $20.00 |
| Sep 10, 2024 | Jefferies | Akash Tewari | Buy | Upgrade | $16.00 |
| Aug 7, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $23.00 |
Relay Therapeutics Inc. (RLAY) Competitors
The following stocks are similar to Relay Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Relay Therapeutics Inc. (RLAY) Financial Data
Relay Therapeutics Inc. has a market capitalization of $620.45M with a P/E ratio of 0.0x. The company generates $10.01M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -3,854.0% and return on equity of -44.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Relay Therapeutics Inc. (RLAY) Business Model
About Relay Therapeutics Inc.
Biotechnology company focused on drug discovery.
Relay Therapeutics generates revenue by developing innovative therapeutics using dynamic protein motion analysis to create targeted treatments for oncology and genetic diseases. The company combines computational and experimental techniques to enhance drug discovery and precision medicine, positioning itself as a leader in biotechnology.
Relay Therapeutics is dedicated to addressing complex diseases and improving patient outcomes through personalized medicine. Its focus on oncology and genetic diseases reflects a commitment to advancing healthcare by tailoring treatments to individual patient profiles.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
261
CEO
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Country
United States
IPO Year
2020
Website
www.relaytx.comRelay Therapeutics Inc. (RLAY) Latest News & Analysis
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
10 days agoRelay Therapeutics (RLAY) is technically in oversold territory, suggesting potential for a trend reversal, supported by analysts revising earnings estimates higher.
Relay Therapeutics may be poised for a rebound as it shows oversold conditions and analysts are raising earnings estimates, signaling potential upside for investors.
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
17 days agoPhase 3 ReDiscover-2 trial for RLY-2608 plus fulvestrant is set to begin in mid-2025, targeting HR+/HER2- metastatic breast cancer with specific mutations.
The initiation of the Phase 3 trial for RLY-2608 could indicate potential advancements in treatment options for a specific breast cancer population, impacting future revenue and stock performance.
Relay Therapeutics, Inc. (Nasdaq: RLAY) will participate in TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at 1:50 p.m.
Relay Therapeutics' participation in major conferences signals engagement with investors and potential for partnership, which may positively influence stock performance and market perception.
Relay Therapeutics (Nasdaq: RLAY) will report its Q4 and full year 2024 financial results and corporate highlights on February 26, 2025, after U.S. market close.
Relay Therapeutics' upcoming financial results and corporate highlights could indicate its growth potential and impact stock performance, influencing investor sentiment and market positioning.
Relay Therapeutics is developing RLY-2608 for breast cancer and has a strong cash position until 2027. However, it reported no Q3 2024 revenue and rising losses. Out-licensing RLY-4008 to Elevar could bring up to $500 million.
Relay Therapeutics' solid cash position and potential milestone from RLY-4008 highlight financial stability, but lack of revenue and rising losses raise questions about future profitability and expense management.
Relay Therapeutics, Inc. (Nasdaq: RLAY) will have its CEO, Sanjiv Patel, present at the J.P. Morgan Healthcare Conference on January 14, 2025, at 7:30 a.m. PT, focusing on its drug discovery innovations.
Relay Therapeutics' participation in a major healthcare conference highlights its potential to attract investor interest and showcase advancements in drug discovery, impacting stock performance.
Frequently Asked Questions About RLAY Stock
What is Relay Therapeutics Inc.'s (RLAY) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Relay Therapeutics Inc. (RLAY) has a median price target of $18.00. The highest price target is $30.00 and the lowest is $12.00.
Is RLAY stock a good investment in 2025?
According to current analyst ratings, RLAY has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RLAY stock?
Wall Street analysts predict RLAY stock could reach $18.00 in the next 12 months. This represents a 391.8% increase from the current price of $3.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Relay Therapeutics Inc.'s business model?
Relay Therapeutics generates revenue by developing innovative therapeutics using dynamic protein motion analysis to create targeted treatments for oncology and genetic diseases. The company combines computational and experimental techniques to enhance drug discovery and precision medicine, positioning itself as a leader in biotechnology.
What is the highest forecasted price for RLAY Relay Therapeutics Inc.?
The highest price target for RLAY is $30.00 from Bradley Canino at Stifel, which represents a 719.7% increase from the current price of $3.66.
What is the lowest forecasted price for RLAY Relay Therapeutics Inc.?
The lowest price target for RLAY is $12.00 from at , which represents a 227.9% increase from the current price of $3.66.
What is the overall RLAY consensus from analysts for Relay Therapeutics Inc.?
The overall analyst consensus for RLAY is bullish. Out of 12 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are RLAY stock price projections?
Stock price projections, including those for Relay Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
